- Home
- UHG vs COYA Comparison
UHG vs COYA Comparison
Compare UHG & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHG | COYA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.1M | 126.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | UHG | COYA |
|---|---|---|
| Price | $2.10 | $4.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | ★ 311.2K | 302.7K |
| Earning Date | 03-11-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,113,017.00 | $3,987,706.00 |
| Revenue This Year | N/A | $70.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $3.94 |
| 52 Week High | $4.78 | $8.29 |
Technical Indicators
Market Signals| Indicator | UHG | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 49.15 |
| Support Level | $1.91 | $4.41 |
| Resistance Level | $2.16 | $4.97 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 78.10 | 79.09 |
Price Performance
Historical ComparisonAbout UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.